Overview

A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients

Status:
Active, not recruiting
Trial end date:
2022-06-02
Target enrollment:
Participant gender:
Summary
The primary purpose is to evaluate the safety and tolerability of OP-101 and secondary purpose is to determine the effect of OP-101 reducing proinflammatory cytokines after a single dose in severe COVID-19 Patients.
Phase:
Phase 2
Details
Lead Sponsor:
Orpheris, Inc.